anoth sunshini quarter volum lift cgm sale
anoth day sun sale street
strong opex control profit bump sale
outlook patient adopt outstrip expect us
commerci new patient pipelin doubl year ago
ou sale growth y/i shockingli strong price hot
topic earn call price headwind seen cgm
busi increasingli move toward pharmaci channel worri us
long term given patient access benefit said
quarter concern may eventu see price
pressur payor face competit worri
remain distant cloud horizon co pipelin full
includ dispos glucos record devic develop outsid
verili partnership intend nearli anyon increas sale
ep forecast remain neutral base valuat
patient volum show sign slow launch
month old patient use system
adopt ou particularli strong though remain
seen whether level growth sustain think move
toward pharma channel add fuel fire
pharma channel price headwind equat
hit sale growth full quarter dynam
slate neg impact think robust
patient uptak off-set volum uplift
continu even headwind anniversari
new addit pipelin learn work
dispos glucos record product anyon y/o could
use co remain focus verili collab late
offer non-intens popul
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
third quarter total revenu came
forecast gross margin exactli line project
control oper spend well sg expens
percentag revenu significantli model bp bp
lower respect compani report profit adjust net incom
basi adj ep cent better lp estim
increas patient add patient re-ord rate averag sensor kit
order per quarter increas forward revenu forecast increas
signific sensor revenu line believ strong adopt
increas patient volum push recur revenu busi
higher faster pace anticip model
revenu almost revis guidanc target also increas
sale estim
margin continu model gross margin y/i
growth oper expens chang gross margin
outlook sinc expect addit capac requir
meet higher product demand somewhat off-set benefit higher
revenu howev slightli decreas oper spend assumpt
percentag revenu combin higher
revenu control opex spend increas ep outlook meaning
actualsbtig estimate variancetot revenu net incom spend spend opex spend btig estim compani filingsvari
model ep prior prior
prior
rate neutral believ current multipl
estim ntm ev/sal expens given potenti price pressur
face increas competit valuat seem support
investor concern competit price like
immedi and/or increas spend expect exceed
revenu estim wonder happen price risk
rate includ competit increas spend chang revenu growth
rate fda product recal reimburs price pressur
bpsebit bp btig estim compani filingsnewold changentm inc ingnnot sciencesexasbuy medicalwmginot factset data btig estimatespr profitev/salescagrcompanytickerr ptpricemarket cap
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
